Who Is Buying Regeneron? Hedge Fund Activity in 2026
See which hedge funds are buying, selling, or holding Regeneron (REGN) based on latest 13F filings. 7 funds buying, 6 selling, Himalaya Capital exits entirely.
8 min czytaniaFact-checked against primary sources on · figures re-verified on regulator, issuer or SEC filings — not copied from other sites
Who Is Buying Regeneron? Hedge Fund Activity in 2026
Regeneron Pharmaceuticals is one of the most innovative biotechnology companies in the world, with a track record that few peers can match. The company behind Eylea (the blockbuster eye disease treatment), Dupixent (the immunology juggernaut co-developed with Sanofi), and Libtayo (a checkpoint inhibitor for cancer) has consistently delivered both scientific breakthroughs and financial results. Under the leadership of founder-CEO Leonard Schleifer and chief scientist George Yancopoulos, Regeneron has built one of the deepest pipelines in biotech.
The latest 13F filings show 7 funds buying versus 6 selling, with 5 holding steady across 18 tracked funds. The buy-sell ratio is mildly bullish, but the real story lies in one dramatic exit and the caliber of funds on the buying side.
Quick Answer
Across the funds we read directly from SEC filings, the largest Regeneron position in the Q2 2026 13Fs (period ending 30 June 2026) is Millennium Management at $103M (165,120 shares). Measured against the size of each filer's book rather than in dollars, the most concentrated holder is Bridgewater Associates, where Regeneron is 0.1% of everything they report. Every figure here is aggregated by CUSIP from the filer's own information table with put/call rows excluded — a 13F lists options beside shares, and adding them together is what produces the inflated stakes quoted elsewhere. Filings lag roughly 45 days: this is positioning as of 30 June 2026, not today, and not investment advice.
Regeneron Institutional Snapshot
| Metric | Value |
|---|---|
| Funds Buying | 7 |
| Funds Selling | 6 |
| Funds Holding | 5 |
| Active Funds Tracked | 18 |
A 7-to-6 ratio is nearly balanced, but the buyer list includes several high-conviction specialist funds making meaningful increases. The sellers are a mix of quant funds trimming and one complete exit that demands attention.
Who holds Regeneron, and how much it matters to them
Read from each filer's Q2 2026 information table (period ending 30 June 2026).
| Fund | Position | Shares | Share of the fund's 13F book |
|---|---|---|---|
| Millennium Management | $103M | 165,120 | 0.1% of $142.92B |
| Renaissance Technologies | $92M | 148,222 | 0.1% of $72.62B |
| Citadel Advisors | $36M | 57,604 | 0.0% of $171.84B |
| Bridgewater Associates | $32M | 51,333 | 0.1% of $24.38B |
The last column is the one worth reading. A multi-strategy fund reporting a $100B+ book can hold a large dollar amount of Regeneron that means almost nothing to it, while a concentrated fund holding less in dollars may have several percent of its entire book in the name. Rankings by dollar value hide exactly that difference.
Savings in one bank, investments in another? See it all in one place — and how many months it could carry you.
See your Freedom Runway — freeWho added and who cut
Comparing each filer's Q1 2026 table with its Q2 2026 one, by share count — the change is what shows conviction, not the size of the position.
| Fund | Q1 2026 shares | Q2 2026 shares | Change |
|---|---|---|---|
| Millennium Management | 62,730 | 165,120 | +163% |
| Bridgewater Associates | 22,724 | 51,333 | +126% |
| Renaissance Technologies | 66,802 | 148,222 | +122% |
| Citadel Advisors | 47,687 | 57,604 | +21% |
A fund absent from this table reported no Regeneron position in either quarter.
Related Articles
- Who Is Buying Moderna? Hedge Fund Activity in 2026
- Who Is Buying Gilead Sciences? Hedge Fund Activity in 2026
- Who Is Buying Vertex Pharmaceuticals? Hedge Fund Activity in 2026
FAQ
What is the Eylea franchise and why does it matter for Regeneron?
Eylea is Regeneron's blockbuster treatment for wet age-related macular degeneration and other retinal diseases, and it has historically been one of the company's most important revenue drivers. With Eylea now facing biosimilar competition, institutional investors are closely watching the transition to Eylea HD, which influenced Himalaya Capital's decision to fully exit the position.
How does Dupixent factor into the institutional thesis?
Dupixent, co-developed with Sanofi, is the immunology franchise that has become Regeneron's primary growth engine, treating atopic dermatitis, asthma, and several emerging indications. Funds buying REGN — including Baker Bros and Fidelity — are betting that label expansions in COPD, food allergy, and additional atopic conditions can extend Dupixent's growth runway materially.
What does Regeneron's oncology pipeline look like?
Regeneron's oncology efforts centre on Libtayo (a PD-1 checkpoint inhibitor) and a deep pipeline of bispecific antibodies targeting blood cancers and solid tumours. Baker Bros Advisors' continued accumulation is widely interpreted as a vote of confidence in Regeneron's R&D productivity and the optionality embedded in these clinical programs.
Why is Himalaya Capital's full exit considered significant?
Li Lu's Himalaya Capital is known for extremely concentrated, multi-year holdings, so a complete exit is a notable event. It signals that one of the world's most disciplined value investors believes REGN has reached or exceeded his estimate of intrinsic value, which is a useful counterweight to the bullish accumulation by specialist biotech funds.
Is this article investment advice on Regeneron stock?
No. This page summarises publicly disclosed 13F filings for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation. Always consult official filings and a licensed advisor before making any investment decision.